Exelixis Inc. reported a 31% increase in revenue for Q1 2025, driven by strong sales of CABOMETYX, leading to raised full-year revenue guidance and increased stock price targets from analysts.

Exelixis Inc. exceeded first-quarter profit expectations, sending its stock surging and leaving investors optimistic about the company’s future prospects in the biotech industry.

Exelixis Inc. shares surged as the biotech company reported a Q1 profit that exceeded market expectations, solidifying its position as a leader in the sector.